Navigation Links
Effective prostate cancer treatment discovery
Date:2/25/2010

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers the most common cancer in Australian men.

For more than 60 years the main way to treat men with prostate cancer has involved removing the hormones that fuel growth of the cancer cells. Although initially effective this treatment inevitably fails and when the tumour growth resumes, the disease in incurable. The team, from the Prostate & Breast Cancer Research Program, has discovered a way to treat these potentially fatal diseased cells, which remain in a patient after they have undergone hormone treatment.

The findings have been published in the prestigious medical journal PNAS.

Associate Dean, Research Centres & Institutes and co-author Professor Gail Risbridger said the studies provided proof of the controversial concept that estrogens (hormones mainly thought as being important for women) could be good for men and used therapeutically to treat prostate cancer.

"The research showed that drugs that activate one of the two estrogen receptors, causes cell death. Most commonly cell death in patients with prostate cancer is achieved by withdrawing androgens (male hormones) which results in castration," Professor Risbridger said.

"Although the bulk of the tumour is removed by castration, some cells remain and these castrate-resistant cells are the ones that give rise to recurrent incurable disease"

The team used a drug developed to selectively and specifically activate the beta estrogen receptor in the prostate.

"It not only inhibits the growth of prostate cancer but also kills off cancer cells that are resistant to conventional treatment such as androgen deprivation therapy, more commonly known as castration therapy and does so using a mechanism that is different to castration." Professor Risbridger said.

The team made the discovery in animal models, and then successfully replicated laboratory results using human cells and tissues from patients with prostate cancer.

"The team at Monash University has discovered how this compound working through the beta receptors targets a small, but very important, population of cells in the tumour. It is a significant piece of the puzzle that will help medical research in this field an achievement that could eventually enhance treatment options for patients around the world with advanced prostate cancer." Professor Risbridger said.

Prostate cancer is the most common cancer in Australian men and is the second most common cause of cancer deaths in men. Each year in Australia, close to 3,300 men die of prostate cancer - equal to the number of women who die from breast cancer annually. About 20,000 new cases are diagnosed in Australia every year and one in nine men will develop prostate cancer in their lifetime. Current treatments of prostate cancer include hormone therapy however patient side effects can be devastating.

"This research also has personal meaning and provides me with the imperative to conduct basic biomedical research where the fundamental outcomes such as those we describe, may ultimately translate into more effective ways to treat prostate cancer" Professor Risbridger said.


'/>"/>

Contact: Samantha Blair
samantha.blair@adm.monash.edu.au
61-399-034-841
Monash University
Source:Eurekalert

Related medicine news :

1. Study Shows Sani-Bag+ to be an Effective Microbial Barrier
2. Mammogram Plus MRI Cost-Effective in High-Risk Women
3. Mammogram Plus MRI Seems Cost-Effective in High-Risk Women
4. Two Sepsis Treatments Look Equally Effective
5. New drug for kidney transplant recipients effective in humans
6. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
7. Charging less for more effective treatments could reduce health care costs while improving health
8. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
9. Neuroimaging study may pave way for effective Alzheimers treatments
10. Gastric Banding Most Effective for Obese Teens
11. Low forms of cyclin E reduce breast cancer drugs effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown Health ... Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , The ... tax credit to individuals and corporations which donate directly to a “rural hospital” in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating ... new location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. ... Smart TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly ... for the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL ... KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016  In the ... projected to shift from systems dependent on CRTs monitors ... types of modality CRT Medical monitors and will ... are a host of foreseeable benefits to this ... will existing modalities have to be replaced in ...
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... Jersey , April 29, 2016 ... Suite for Life Sciences, Product Development Capabilities in ... Life Science Customer Base . ... provider, today announced the acquisition of Skura Corporation,s ... global leader in adaptive sales enablement technology for ...
Breaking Medicine Technology: